Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Holy Stone Healthcare Co., Ltd
In the individual patient expanded access, the subject who was enrolled in Phase 1 trial (Study Number: HS-CA102N-101) Part 2 (dose expansion) and had completed at least 12 treatment cycles with CA102N combined with trifluridine /tipiracil (LONSURF) will be provided access to treatment with CA102N (0.72 mg/kg Nimesulide Equivalent of CA102N).
Age
Any age
Sex
Any
Healthy volunteers
Not accepted
You may be eligible if
\-
You may not be if
\-
Clareo Health | Individual Patient Expanded Access to CA102N
